Head-to-head · WeighScore
Enhance MD vs Ilant Health
The verdict
Enhance MD takes it — 84.8/100 to 56.8/100.
Enhance MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A transparently tiered compounded program — semaglutide $212/mo (first month $112), tirzepatide $280, a $169 microdose, and a $322 combo — backed by six-month lab testing and provider care, with NAD+ on the side.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Enhance MD | Ilant Health |
|---|---|---|
| WeighScore | 84.8/100 | 56.8/100 |
| Grade | B | C |
| Scorecard rank | #11 | #408 |
| Semaglutide | $212/mo | Not disclosed |
| Tirzepatide | $280/mo | Not disclosed |
| Coverage | Not publicly listed | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #11 · B
Strengths
- Transparent tiered pricing across sema, tirz, microdose, and combo
- Dose-flat — the price does not step up as you titrate
- Six-month lab testing plus provider-led care
- NAD+ longevity adjacency available
Where it loses points
- Compounded only — no brand-name Ozempic/Wegovy or Mounjaro/Zepbound
- No oral or sublingual route
- States served are not published
- Higher entry price than the cheapest compounded programs
Graded #408 · C
Strengths
- Value-based, outcomes-driven obesity care model
- Includes GLP-1 medications with transparent drug pricing for sponsors
- Care team of board-certified obesity providers and behavioral specialists
- Dietitians and peer navigators support adherence
- Data-driven stratification targets the right interventions
Where it loses points
- Distributed via employers and health plans, not direct cash-pay
- Individuals generally cannot enroll without sponsor coverage
- No public consumer pricing for GLP-1
- Access gated behind organizational buyers
- Not suited to consumers wanting direct-to-door GLP-1
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.